<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02810600</url>
  </required_header>
  <id_info>
    <org_study_id>Gallium DOTATATE/PET scan</org_study_id>
    <nct_id>NCT02810600</nct_id>
  </id_info>
  <brief_title>Study to Measure the Safety of 68Ga-DOTA-TATE PET/CT in the Diagnosis of Tumors Expressing Somatostatin Receptors</brief_title>
  <acronym>PET/Ga68</acronym>
  <official_title>Phase II Study to Measure the Safety of 68Ga-DOTA-TATE PET/CT in the Diagnosis of Tumors Expressing Somatostatin Receptors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre de recherche du Centre hospitalier universitaire de Sherbrooke</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre de recherche du Centre hospitalier universitaire de Sherbrooke</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase-II, prospective, open label, no control group to assess the safety of 68Ga-DOTA-TATE
      injection in patients with suspected or diagnosed with tumors expressing somatostatin
      receptors. Each included patient will receive an administered dose of 50 mcg or less of the
      peptide (DOTA-TATE) and a range of activity between 100 - 200 MBq of 68Ga-DOTA-TATE.

      The efficacy of 68Ga-DOTA-TATE in assessing this kind of tumors has been proved by numerous
      studies.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>2 Days</target_duration>
  <primary_outcome>
    <measure>Record all adverse events</measure>
    <time_frame>June 2016-June 2018</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Neuroendocrine Tumors</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Gallium-68 DOTA TATE PET scan</intervention_name>
    <description>One PET/CT scan using Gallium-68 DOTA TATE</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with suspected or diagnosed with tumors expressing somatostatin receptors
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with suspected or proven tumors expressing Somatostatin receptors

          2. Informed consent by patient (or parents if patient is less than 18 years of age)

        Exclusion Criteria:

          1. Pregnancy (confirmed). In the case of a diagnostic procedure in a patient who is or
             may be pregnant, a clinical decision is necessary considering the benefits against the
             possible harm of carrying out any procedure.

          2. Patient refusal to participate.

          3. Impossibility to tolerate a decubitus position for 25 minutes

          4. Prior allergic reaction to DOTA-TATE or somatostatin analogs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Helena Senta, PhD</last_name>
    <phone>819-346-1110</phone>
    <phone_ext>13660</phone_ext>
    <email>helena.senta@usherbrooke.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Éric Lavallée, TIM</last_name>
    <phone>819-346-1110</phone>
    <phone_ext>12887</phone_ext>
    <email>eric.lavallee2@usherbrooke.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre hospitalier universitaire de Sherbrooke</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Eric Turcotte, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 16, 2016</study_first_submitted>
  <study_first_submitted_qc>June 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2016</study_first_posted>
  <last_update_submitted>July 20, 2017</last_update_submitted>
  <last_update_submitted_qc>July 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroendocrine Tumors</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Somatostatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

